Vaxcyte (NASDAQ:PCVX) EVP Jim Wassil Sells 1,381 Shares

Vaxcyte, Inc. (NASDAQ:PCVX) EVP Jim Wassil sold 1,381 shares of the business’s stock in a transaction dated Friday, September 4th. The stock was sold at an average price of $61.16, for a total transaction of $84,461.96. Following the sale, the executive vice president directly owned 152,228 shares of the company’s stock, valued at approximately $9,310,264.48. The trade was a 0.90% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Jim Wassil also recently made the following trade(s):

• On Wednesday, September 9th, Jim Wassil sold 1,334 shares of Vaxcyte stock. The shares were sold at an average price of $59.52, for a total transaction of $79,399.68.
• On Tuesday, September 1st, Jim Wassil sold 3,477 shares of Vaxcyte stock. The shares were sold at an average price of $61.07, for a total value of $212,340.39.
• On Monday, August 3rd, Jim Wassil sold 2,250 shares of Vaxcyte stock. The stock was sold at an average price of $53.86, for a total value of $121,185.00.
• On Wednesday, July 1st, Jim Wassil sold 2,250 shares of Vaxcyte stock. The stock was sold at an average price of $56.33, for a total value of $126,742.50.

Vaxcyte Stock Down 1.4%

PCVX stock opened at $59.51 on Thursday. The firm has a market capitalization of $8.86 billion, a PE ratio of -7.80 and a beta of 1.22. Vaxcyte, Inc. has a twelve month low of $30.81 and a twelve month high of $65.00. The stock’s 50 day moving average is $58.41 and its 200-day moving average is $56.32.

Vaxcyte (NASDAQ:PCVX) last announced its quarterly earnings results on Wednesday, August 5th. The company reported ($1.97) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.06) by $0.09. During the same period in the prior year, the company posted ($1.22) EPS. On average, equities research analysts anticipate that Vaxcyte, Inc. will post -7.6 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Vaxcyte

Several large investors have recently made changes to their positions in PCVX. Smartleaf Asset Management LLC boosted its holdings in shares of Vaxcyte by 156.2% in the 4th quarter. Smartleaf Asset Management LLC now owns 597 shares of the company’s stock worth $27,000 after buying an additional 364 shares during the last quarter. Caitong International Asset Management Co. Ltd increased its holdings in Vaxcyte by 1,463.4% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 641 shares of the company’s stock worth $30,000 after buying an additional 600 shares during the last quarter. IFP Advisors Inc raised its position in Vaxcyte by 72.8% in the second quarter. IFP Advisors Inc now owns 560 shares of the company’s stock worth $33,000 after acquiring an additional 236 shares during the period. EverSource Wealth Advisors LLC raised its position in Vaxcyte by 33.0% in the fourth quarter. EverSource Wealth Advisors LLC now owns 741 shares of the company’s stock worth $34,000 after acquiring an additional 184 shares during the period. Finally, CIBC Private Wealth Group LLC boosted its stake in Vaxcyte by 22,500.0% in the third quarter. CIBC Private Wealth Group LLC now owns 1,356 shares of the company’s stock valued at $49,000 after acquiring an additional 1,350 shares during the last quarter. 96.78% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research analysts recently weighed in on PCVX shares. Zacks Research raised shares of Vaxcyte from a “strong sell” rating to a “hold” rating in a research report on Wednesday, August 12th. Wall Street Zen upgraded shares of Vaxcyte from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 8th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Vaxcyte in a research report on Monday, July 6th. Five analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $86.00.

Vaxcyte Company Profile

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company’s platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.

Vaxcyte’s lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.